superior industrial supply co. blue logo
0

Blog Layout

DOB

DOM, DOB, STP, 2C-B, 2C-E, 2C-1

DOM, DOB, STP, 2C-b, 2C-e, 2C-i, MDA Many chemical variations of mescaline and amphetamine (Dom-Dob-STP-2c-b-mda) have been synthesized for their “feel good” effects. MDMA (Ecstasy) is the most popular and widely abused variation used today. DOM, DOB, STP, 2C-b, 2C-e, 2C-i, MDA DOM (4-Methyl-2,5-dimethoxyamphetamine) was introduced to the San Francisco drug scene in the late 1960’s…

Hallucinogens, DOM, DOB, STP, 2C-b, 2C-e, 2C-i, MDA, are found in plants and fungi or are synthetically Hallucinogens and are among the oldest known group of drugs used produced and are among the oldest known group of drugs used for their ability to alter human perception and mood.


Throughout the drug discovery process, pharmaceutical companies, academic institutions, research institutions, and other organizations publish their studies in scientific journals, books, and patents. This information exchange, which is essential to the legitimate scientific enterprise, can be, and is, used by clandestine chemists who duplicate the technical sophistication used by the research community to manufacture and market a seemingly endless variety of analogs of so-called designer drugs.


The term “designer drug” is a colloquial term that references substances with properties and effects similar to those of stimulant, depressant, hallucinogenic or narcotic drugs but that are chemically modified to evade control as an illicit drug. Although news reports tend to portray the appearance of these substances as a new trend, designer drugs have been in the illicit marketplace for decades. The distinction of today’s designer drugs is the substantial volume and endless variety of designer drugs easily available to the public and the organized, extensive distribution networks utilized by designer drug traffickers.


Since the 1970s, domestic clandestine chemists have attempted to manipulate the molecular structures of controlled substances to create synthetic drugs that would have the same pharmacologic properties of a controlled drug, but not expose the chemist or distributor to criminal violations under the Federal Controlled Substances Act (CSA) or similar state statutes. Since these drugs are created in a clandestine laboratory, no manufacturing standards or safety and efficacy studies, such as those required by the Food and Drug Administration (FDA) with respect to pharmaceutical drugs, ensure the safety of the products ingested. Designer drugs were distinguished from traditional illicit drugs of abuse due to the lack of history and appreciation for the short and long-term health effects of use. Historically, the introduction of “designer drugs,” Dom-Dob-STP-2c-b-mda, into the marketplace was generally similar to that of illicit controlled substances: covert meetings and sales on street corners, back alleys, and in dark clubs. During this time period, the infusion of these drugs into the illicit marketplace wreaked havoc in certain areas of the country.


In the 1970s and 1980s, clandestine chemists introduced synthetic alternatives to the Schedule II drug fentanyl into the illicit marketplace. These drugs were distributed to heroin abusers who were unaware that the drug they were purchasing was 100 to 500 times more potent than morphine. Drug abusers were the unknowing test subjects used to determine the viability of the substances as a replacement for controlled narcotics. This uncontrolled experimentation resulted in overdose deaths in concentrated areas of the country with law enforcement authorities scrambling to identify the drug and locate the clandestine laboratories and chemists that produced the substances. In some instances, it wasn’t the strength of the drug, but its toxic contaminants that ultimately harmed the users. For example, a domestic chemist was attempting to manufacture MPPP, a synthetic alternative to the Schedule II drug meperidine (Demerol®). During the manufacturing process, the chemist manufactured MPPP that was contaminated with MPTP, a neurotoxin that caused end-stage Parkinson’s symptoms (involuntary motor movement) in the user. Again, the clandestine chemist was using illicit drug users as subjects for his own personal laboratory experiment, with tragic results. At the time, these synthesized drugs were not controlled substances under the CSA and therefore there was little, if any, criminal exposure and little incentive to stop manufacturing and producing the drugs. The possibility of synthesizing a non-controlled substance that could produce millions of dollars in income was too enticing to stop experimenting on a readily-available number of test subjects.



SOURCE: DEA

By Bob Hansen January 29, 2022
Zyprexa (Olanzapine) is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder. More information/images in the Prescription Drug Brochure. When you receive Zyprexa extended-release injection, the medication is usually released slowly into your blood over a period of time. However, when you receive olanzapine extended-release injection, there is a small chance that olanzapine may be released into your blood too quickly. If this happens, you may experience a serious problem called Post-injection Delirium Sedation Syndrome (PDSS). If you develop PDSS, you may experience dizziness, confusion, difficulty thinking clearly, anxiety, irritability, aggressive behavior, weakness, slurred speech, difficulty walking, muscle stiffness or shaking, seizures, drowsiness, and coma (loss of consciousness for a period of time). You are most likely to experience these symptoms during the first 3 hours after you receive the medication. You will receive Zyprexa extended-release injection in a hospital, clinic, or another medical facility where you can receive emergency medical treatment if it is needed. You will need to remain in the facility for at least 3 hours after you receive the medication. While you are in the clinic, the medical staff will watch you closely for signs of PDSS. When you are ready to leave the facility, you will need a responsible person to be with you, and you should not drive a car or operate machinery for the rest of the day. Get emergency medical help right away if you experience any symptoms of PDSS after you leave the facility. A program has been set up to help people receive Zyprexa extended-release injection safely. You will need to register and agree to the rules of this program before you receive olanzapine extended-release injection. Your doctor, the pharmacy that dispenses your medication, and the medical facility where you receive your medication will also need to register. Ask your doctor if you have any questions about this program. For people being treated with olanzapine extended-release injection or Zyprexa injection: Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as olanzapine have an increased chance of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or mini-stroke during treatment. Olanzapine injection and olanzapine extended-release injection are not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is being treated with olanzapine injection or olanzapine extended-release injection. For more information visit the FDA website: http://www.fda.gov/Drugs Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with olanzapine extended-release injection and each time you receive an injection. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide. extended-release injection, the medication is usually released slowly into your blood over a period of time. However, when you receive olanzapine extended-release injection, there is a small chance that olanzapine may be released into your blood too quickly. If this happens, you may experience a serious problem called Post-injection Delirium Sedation Syndrome (PDSS). If you develop PDSS, you may experience dizziness, confusion, difficulty thinking clearly, anxiety, irritability, aggressive behavior, weakness, slurred speech, difficulty walking, muscle stiffness or shaking, seizures, drowsiness, and coma (loss of consciousness for a period of time). You are most likely to experience these symptoms during the first 3 hours after you receive the medication. You will receive olanzapine extended-release injection in a hospital, clinic, or another medical facility where you can receive emergency medical treatment if it is needed. You will need to remain in the facility for at least 3 hours after you receive the medication. While you are in the clinic, the medical staff will watch you closely for signs of PDSS. When you are ready to leave the facility, you will need a responsible person to be with you, and you should not drive a car or operate machinery for the rest of the day. Get emergency medical help right away if you experience any symptoms of PDSS after you leave the facility. A program has been set up to help people receive olanzapine extended-release injection safely. You will need to register and agree to the rules of this program before you receive olanzapine extended-release injection. Your doctor, the pharmacy that dispenses your medication, and the medical facility where you receive your medication will also need to register. Ask your doctor if you have any questions about this program. For people being treated with olanzapine extended-release injection or olanzapine injection: Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and that may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as olanzapine have an increased chance of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or mini-stroke during treatment. Olanzapine injection and olanzapine extended-release injection are not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Talk to the doctor who prescribed this medication if you, a family member, or someone you care for has dementia and is being treated with olanzapine injection or olanzapine extended-release injection. For more information visit the FDA website: http://www.fda.gov/Drugs  Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with olanzapine extended-release injection and each time you receive an injection. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide.
By Bob Hansen January 29, 2022
Zoloft (Sertraline) is included in the class of drugs called selective serotonin reuptake inhibitors (SSRIs). This class of drugs is used to treat depression, anxiety, and other mood disorders.
By Bob Hansen January 29, 2022
Zanaflex (Tizanidine) is a short-acting muscle relaxer. Tizanidine is used to relieve the spasms and increased muscle tone caused by multiple sclerosis (MS, a disease in which the nerves do not function properly and patients may experience weakness, numbness, loss of muscle coordination and problems with vision, speech, and bladder control), stroke, or brain or spinal injury. Tizanidine is in a class of medications called skeletal muscle relaxants. It works by slowing action in the brain and nervous system to allow the muscles to relax. Tizanidine comes as a tablet and a capsule to take by mouth. It is usually taken consistently either always with or always without food two or three times a day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take tizanidine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Tizanidine capsules may be opened and sprinkled on soft foods such as applesauce. Talk to your doctor before opening the capsules because the effects of the medication, when used in this manner, may be different than when swallowing the capsule whole. The medication in the capsule is absorbed differently by the body than the medication in the tablet, so one product cannot be substituted for the other. Each time you have your prescription filled, look at the tablets or capsules in the bottle and make sure that you have received the right product. If you think you received the wrong medication, talk to your doctor or pharmacist right away. Your doctor will probably start you on a low dose of tizanidine and gradually increase your dose, depending on your response to this medication.  Do not stop taking tizanidine without talking to your doctor. If you suddenly stop taking tizanidine, your heart may beat faster and you may have increased blood pressure or tightness in your muscles. Your doctor will probably decrease your dose gradually.
More Posts
Share by: